Is TRDA undervalued or overvalued in 2026? CirclFi runs Entrada Therapeutics, Inc. through 13 institutional-grade valuation models daily to answer exactly that question. Our models include Bayesian DCF (10K Monte Carlo simulations with jump-diffusion), Earnings Power Value (Greenwald zero-growth analysis), EROIC Spread (McKinsey reinvestment framework), Markov DDM (regime-switching dividend model), and 9 more advanced frameworks.
Our proprietary Quality of Company (QOC) score evaluates TRDA across 32 fundamental signals — profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. The Value Trap algorithm cross-references apparent undervaluation against deteriorating fundamentals to flag stocks that look cheap but carry hidden risk.
How We Calculate TRDA Fair Value
Unlike simple P/E ratio screens or analyst price targets, CirclFi computes intrinsic value from first principles using SEC EDGAR financial data. Each of our 13 models — Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, ML-RIV, Dynamic NAV, PWERM, Regime Cross-Sectional, Sentiment SOTP, CUCE Ensemble, FTNN Topology, and RCMH-DCF — produces an independent fair value estimate with a confidence score. These are then combined using our CUCE Ensemble method — a correlation-adjusted inverse-variance weighting system that automatically dampens outlier models and amplifies agreement.
TRDA Valuation Summary
Entrada Therapeutics, Inc. currently trades at $6.56 with 9 of 13 valuation models active. The company operates in the — sector. CirclFi's Quality of Company score for TRDA is 4.8/10, and the Value Trap score is 24 (SAFE). This analysis is updated automatically after each market close using the latest SEC EDGAR filings and market data.